Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis		Drug
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	prostate cancer
ICD-0-3	C61.9
Methods	cell transfections, cell metastasis assays, antibody and immunoblot, Microarray analysis, xenograft animal model, RNA isolation, qRT-PCR, chromatin immunoprecipitation (ChIP)-qPCR, immunofluorescence staining, in situ hybridization, oligo pulldown, luciferase reporter assay, northern blotting, RNA immunoprecipitation (RIP) assays, CRISPR/Cas9-mediated genomic editing, p53 knockout
Sample	PCa tissues, cell lines PC3, LNCaP, DU145, RWPE-1
Expression Pattern	down-regulated
Function Description	a Amotl1-derived circRNA, termed circAMOTL1L, is downregulated in human PCa, and that decreased circAMOTL1L facilitates PCa cell migration and invasion through downregulating E-cadherin and upregulating vimentin, thus leading to EMT and PCa progression. Mechanistically, we demonstrate that circAMOTL1L serves as a sponge for binding miR-193a-5p in PCa cells, relieving miR-193a-5p repression of Pcdha gene cluster (a subset of the cadherin superfamily members). Accordingly, dysregulation of the circAMOTL1L-miR-193a-5p-Pcdha8 regulatory pathway mediated by circAMOTL1L downregulation contributes to PCa growth in vivo. Further, we show that RBM25 binds directly to circAMOTL1L and induces its biogenesis, whereas p53 regulates EMT via direct activation of RBM25 gene. These findings have linked p53/RBM25-mediated circAMOTL1L-miR-193a-5p-Pcdha regulatory axis to EMT in metastatic progression of PCa.
Pubmed ID	30531834
Year	2018
Title	Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway

External Links